<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Cardiovasc Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Am J Cardiovasc Drugs</journal-id><journal-title-group><journal-title>American Journal of Cardiovascular Drugs</journal-title></journal-title-group><issn pub-type="ppub">1175-3277</issn><issn pub-type="epub">1179-187X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26994003</article-id><article-id pub-id-type="pmc">4969791</article-id><article-id pub-id-type="publisher-id">167</article-id><article-id pub-id-type="doi">10.1007/s40256-016-0167-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sohn</surname><given-names>Il Suk</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chong-Jin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Oh</surname><given-names>Byung-Hee</given-names></name><address><email>ohbhmed@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Taek-Jong</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Chang-Gyu</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Byung-Soo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Woo-Baek</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><collab>For the Investigators</collab></contrib><aff id="Aff1"><label>1</label>Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea </aff><aff id="Aff2"><label>2</label>Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro(28 Yongondong), Jongno-gu, Seoul, 110-744 Republic of Korea </aff><aff id="Aff3"><label>3</label>Pusan National University Hospital, Busan, Republic of Korea </aff><aff id="Aff4"><label>4</label>Korea University Guro Hospital, Seoul, Republic of Korea </aff><aff id="Aff5"><label>5</label>Daedong Hospital, Busan, Republic of Korea </aff><aff id="Aff6"><label>6</label>Yeouido St. Mary&#x02019;s Hospital of the Catholic University of Korea, Seoul, Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>16</volume><fpage>139</fpage><lpage>139</lpage><permissions><copyright-statement>&#x000a9; Springer International Publishing Switzerland 2016</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e85" ext-link-type="doi" xlink:href="10.1007/s40256-015-0156-x"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-015-0156-x</title><p>Errors have subsequently been identified in the original publication, and the following corrections should be noted:</p><p>Abstract, Results section, lines 9&#x02013;11 which previously read:</p><p>After 8&#x000a0;weeks of double-blind treatment, the changes in msDBP were &#x02212;9.50 (8.46) mmHg in the OM/AML/HCTZ group and &#x02212;4.23 (7.41) mmHg in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups).</p><p>Should read:</p><p>After 8&#x000a0;weeks of double-blind treatment, the changes in msDBP were &#x02212;11.39 (8.34) mmHg in the OM/AML/HCTZ group and &#x02212;5.74 (9.22) mmHg in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups).</p><p>Results, Section&#x000a0;3.2 Efficacy, para 1, lines 2&#x02013;3 which previously read:</p><p>After 8&#x000a0;weeks of double-blind treatment, the changes in msDBP were &#x02212;9.50 (8.46) mmHg in the OM/AML/HCTZ group and &#x02212;4.23 (7.41) mmHg in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups; Fig.&#x000a0;2a).</p><p>Should read:</p><p>After 8&#x000a0;weeks of double-blind treatment, the changes in msDBP were &#x02212;11.39 (8.34) mmHg in the OM/AML/HCTZ group and &#x02212;5.74 (9.22) mmHg in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups; Fig.&#x000a0;2a).</p><p>Results, Section&#x000a0;3.2 Efficacy, para 2, lines 2&#x02013;5 which previously read:</p><p>The changes in msDBP and msSBP from randomization to after 4&#x000a0;weeks of treatment were &#x02212;11.39 (8.34) mmHg and &#x02212;14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline) and &#x02212;5.74 (9.22) mmHg and &#x02212;7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups; Fig.&#x000a0;2).</p><p>Should read:</p><p>&#x02026;The changes in msDBP and msSBP from randomization to after 4&#x000a0;weeks of treatment were &#x02212;9.50 (8.46) mmHg and &#x02212;14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline) and &#x02212;4.23 (7.41) mmHg and &#x02212;7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 vs. baseline; both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 between groups; Fig.&#x000a0;2).</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s40256-015-0156-x.</p></fn></fn-group></back></article>